Efficacy analysis of tyrosine kinase inhibitor combinations in phase II clinical trials of non-small cell lung cancer
This thesis is submitted in partial fulfillment of the requirements for the degree of Bachelor of Pharmacy, 2023.
| Autore principale: | |
|---|---|
| Altri autori: | |
| Natura: | Tesi |
| Lingua: | English |
| Pubblicazione: |
Brac University
2024
|
| Soggetti: | |
| Accesso online: | http://hdl.handle.net/10361/23693 |
| id |
10361-23693 |
|---|---|
| record_format |
dspace |
| spelling |
10361-236932024-07-15T21:03:53Z Efficacy analysis of tyrosine kinase inhibitor combinations in phase II clinical trials of non-small cell lung cancer Flora, Sanzida Alam Azam, Faruque School of Pharmacy, Brac University NSCLC Tyrosine kinase inhibitor Efficacy endpoints Cancer therapy Lung cancer Lung cancer--Treatment Protein-tyrosine kinase--Inhibitors--Therapeutic use This thesis is submitted in partial fulfillment of the requirements for the degree of Bachelor of Pharmacy, 2023. Cataloged from the PDF version of thesis. Includes bibliographical references (pages 17-19). Research is required in the area of non-small cell lung cancer, due to its widespread prevalence. Efforts to enhance the accessibility, evaluative simplicity, and prediction accuracy of endpoints in clinical trials are continuously being pursued. In this study, with particular emphasis on sub-groups, we examine the efficacy and impact of tyrosine kinase inhibitor (TKI) by analyzing endpoints from Phase II clinical trials. We estimated the relative treatment effects for overall survival and progression-free survival using quantitative analysis and appropriate statistical methods. We observed a highly strong and significant positive correlation between OS and PFS (r = 0.79, 95% CI = 0.75–0.83, P < 0.001), while no statistically significant difference was seen across the OS of any treatment size. Additionally, a negative correlation (very weak or no correlation, although statistically significant) between median age and overall survival (r = -0.15, 95% CI = -0.25– -0.04, P = 0.002). However, further investigation in this area of study is required. Sanzida Alam Flora B. Pharmacy 2024-07-15T03:50:57Z 2024-07-15T03:50:57Z ©2023 2023-01 Thesis ID 19146078 http://hdl.handle.net/10361/23693 en Brac University theses are protected by copyright. They may be viewed from this source for any purpose, but reproduction or distribution in any format is prohibited without written permission. 29 pages application/pdf Brac University |
| institution |
Brac University |
| collection |
Institutional Repository |
| language |
English |
| topic |
NSCLC Tyrosine kinase inhibitor Efficacy endpoints Cancer therapy Lung cancer Lung cancer--Treatment Protein-tyrosine kinase--Inhibitors--Therapeutic use |
| spellingShingle |
NSCLC Tyrosine kinase inhibitor Efficacy endpoints Cancer therapy Lung cancer Lung cancer--Treatment Protein-tyrosine kinase--Inhibitors--Therapeutic use Flora, Sanzida Alam Efficacy analysis of tyrosine kinase inhibitor combinations in phase II clinical trials of non-small cell lung cancer |
| description |
This thesis is submitted in partial fulfillment of the requirements for the degree of Bachelor of Pharmacy, 2023. |
| author2 |
Azam, Faruque |
| author_facet |
Azam, Faruque Flora, Sanzida Alam |
| format |
Thesis |
| author |
Flora, Sanzida Alam |
| author_sort |
Flora, Sanzida Alam |
| title |
Efficacy analysis of tyrosine kinase inhibitor combinations in phase II clinical trials of non-small cell lung cancer |
| title_short |
Efficacy analysis of tyrosine kinase inhibitor combinations in phase II clinical trials of non-small cell lung cancer |
| title_full |
Efficacy analysis of tyrosine kinase inhibitor combinations in phase II clinical trials of non-small cell lung cancer |
| title_fullStr |
Efficacy analysis of tyrosine kinase inhibitor combinations in phase II clinical trials of non-small cell lung cancer |
| title_full_unstemmed |
Efficacy analysis of tyrosine kinase inhibitor combinations in phase II clinical trials of non-small cell lung cancer |
| title_sort |
efficacy analysis of tyrosine kinase inhibitor combinations in phase ii clinical trials of non-small cell lung cancer |
| publisher |
Brac University |
| publishDate |
2024 |
| url |
http://hdl.handle.net/10361/23693 |
| work_keys_str_mv |
AT florasanzidaalam efficacyanalysisoftyrosinekinaseinhibitorcombinationsinphaseiiclinicaltrialsofnonsmallcelllungcancer |
| _version_ |
1814309238369943552 |